Insulet Corporation $PODD Shares Sold by Baird Financial Group Inc.

Baird Financial Group Inc. decreased its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 12.1% in the 2nd quarter, Holdings Channel reports. The firm owned 117,326 shares of the medical instruments supplier’s stock after selling 16,089 shares during the quarter. Baird Financial Group Inc.’s holdings in Insulet were worth $17,863,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Larson Financial Group LLC lifted its position in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet during the 4th quarter valued at about $26,000. DV Equities LLC bought a new stake in shares of Insulet during the 4th quarter valued at about $28,000. Elyxium Wealth LLC acquired a new stake in Insulet during the fourth quarter worth about $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new stake in Insulet during the fourth quarter worth about $29,000.

Wall Street Analyst Weigh In

PODD has been the subject of a number of research reports. TD Cowen decreased their target price on Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a research note on Thursday, August 6th. Royal Bank Of Canada dropped their price target on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Truist Financial reissued a “hold” rating and issued a $153.00 price target (down from $210.00) on shares of Insulet in a report on Wednesday, August 5th. Evercore set a $180.00 target price on Insulet in a research report on Monday, July 6th. Finally, Stifel Nicolaus cut their target price on Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Insulet has a consensus rating of “Hold” and an average target price of $195.40.

Insulet Price Performance

Shares of Insulet stock opened at $131.96 on Friday. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The stock has a market cap of $9.15 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 1.06 and a beta of 1.08. The company’s 50-day moving average price is $152.36 and its two-hundred day moving average price is $173.92.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. During the same quarter last year, the firm posted $1.17 EPS. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, sell-side analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.